During the last session, Axsome Therapeutics Inc (NASDAQ:AXSM)’s traded shares were 1.04 million, with the beta value of the company hitting 1.05. At the end of the trading day, the stock’s price was $103.89, reflecting an intraday gain of 1.58% or $1.62. The 52-week high for the AXSM share is $105.00, that puts it down -1.07 from that peak though still a striking 38.29% gain since the share price plummeted to a 52-week low of $64.11. The company’s market capitalization is $5.03B, and the average intraday trading volume over the past 10 days was 1.05 million shares, and the average trade volume was 687.43K shares over the past three months.
Axsome Therapeutics Inc (AXSM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.06. AXSM has a Sell rating from 0 analyst(s) out of 15 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 13 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.03.
Axsome Therapeutics Inc (NASDAQ:AXSM) trade information
Axsome Therapeutics Inc (AXSM) registered a 1.58% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.58% in intraday trading to $103.89, hitting a weekly high. The stock’s 5-day price performance is 10.82%, and it has moved by 15.77% in 30 days. Based on these gigs, the overall price performance for the year is 14.27%. The short interest in Axsome Therapeutics Inc (NASDAQ:AXSM) is 6.62 million shares and it means that shorts have 9.72 day(s) to cover.
The consensus price target of analysts on Wall Street is $135, which implies an increase of 23.04% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $106 and $180 respectively. As a result, AXSM is trading at a discount of -73.26% off the target high and -2.03% off the low.
Axsome Therapeutics Inc (AXSM) estimates and forecasts
Statistics show that Axsome Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Axsome Therapeutics Inc (AXSM) shares have gone up 21.28% during the last six months, with a year-to-date growth rate less than the industry average at -103.75% against 16.50. In the rating firms’ projections, revenue will increase 42.03% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 117.65M as predicted by 16 analyst(s). Meanwhile, a consensus of 12 analyst(s) estimates revenue growth to 121.81M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 71.53M and 75M respectively. In this case, analysts expect current quarter sales to grow by 64.48% and then jump by 62.42% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -35.53%. While earnings are projected to return -3.42% in 2025.
AXSM Dividends
Axsome Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Axsome Therapeutics Inc (NASDAQ:AXSM)’s Major holders
Axsome Therapeutics Inc insiders own 16.70% of total outstanding shares while institutional holders control 81.08%, with the float percentage being 97.33%. RTW INVESTMENTS, LP is the largest shareholder of the company, while 382.0 institutions own stock in it. As of 2024-06-30, the company held over 4.63 million shares (or 9.7784% of all shares), a total value of $373.06 million in shares.
The next largest institutional holding, with 3.74 million shares, is of VANGUARD GROUP INC’s that is approximately 7.8956% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $301.23 million.
Also, the Mutual Funds coming in first place with the largest holdings of Axsome Therapeutics Inc (AXSM) shares are Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.31 shares. This amounts to just over 2.71 percent of the company’s overall shares, with a $136.21 million market value. The same data shows that the other fund manager holds slightly less at 1.02, or about 2.11% of the stock, which is worth about $106.07 million.
